Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Nuclear Medicine and Molecular Imaging
Erschienen in: Nuclear Medicine and Molecular Imaging 1/2013

01.03.2013 | Original Article

Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging

verfasst von: Soyoung Jin, Minyoung Oh, Seung Jun Oh, Jungsu S. Oh, Sang Ju Lee, Sun Ju Chung, Chong Sik Lee, Jae Seung Kim

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Dopamine transporter (DAT) imaging can demonstrate presynaptic dopaminergic neuronal loss in Parkinson’s disease (PD). However, differentiating atypical parkinsonism (APD) from PD is often difficult. We investigated the usefulness of dual-phase F-18 FP-CIT positron emission tomography (PET) imaging in the differential diagnosis of parkinsonism.

Methods

Ninety-eight subjects [five normal, seven drug-induced parkinsonism (DIP), five essential tremor (ET), 24 PD, 20 multiple system atrophy-parkinson type (MSA-P), 13 multiple system atrophy-cerebellar type (MSA-C), 13 progressive supranuclear palsy (PSP), and 11 dementia with Lewy bodies (DLB)] underwent F-18 FP-CIT PET. PET images were acquired at 5 min (early phase) and 3 h (late phase) after F-18 FP-CIT administration (185 MBq). Regional uptake pattern of cerebral and cerebellar hemispheres was assessed on early phase images and striatal DAT binding pattern was assessed on late phase images, using visual, quantitative, and statistical parametric mapping (SPM) analyses.

Results

Striatal DAT binding was normal in normal, ET, DIP, and MSA-C groups, but abnormal in PD, MSA-P, PSP, and DLB groups. No difference was found in regional uptake on early phase images among normal DAT binding groups, except in the MSA-C group. Abnormal DAT binding groups showed different regional uptake pattern on early phase images compared with PD in SPM analysis (FDR < 0.05). When discriminating APD from PD, visual interpretation of the early phase image showed high diagnostic sensitivity and specificity (75.4 % and 100 %, respectively). Regarding the ability to distinguish specific APD, sensitivities were 81 % for MSA-P, 77 % for MSA-C, 23 % for PSP, and 54.5 % for DLB.

Conclusions

Dual-phase F-18 FP-CIT PET imaging is useful in demonstrating striatal DAT loss in neurodegenerative parkinsonism, and also in differentiating APD, particularly MSA, from PD.
Literatur
1.
Hughes AJ, Daniel SE, Lees AJ. The clinical features of Parkinson’s disease in 100 histologically proven cases. Adv Neurol. 1993;60:595–9.PubMed
2.
Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol. 1984;16:278–82.PubMedCrossRef
3.
Bower JH, Dickson DW, Taylor L, Maraganore DM, Rocca WA. Clinical correlates of the pathology underlying parkinsonism: a population perspective. Mov Disord. 2002;17:910–6.PubMedCrossRef
4.
Litvan I, Agid Y, Jankovic J, Goetz C, Brandel JP, Lai EC, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology. 1996;46:922–30.PubMedCrossRef
5.
Seppi K, Yekhlef F, Diem A, Luginger Wolf E, Mueller J, Tison F, et al. Progression of parkinsonism in multiple system atrophy. J Neurol. 2005;252:91–6.PubMedCrossRef
6.
Poewe W, Wenning G. The differential diagnosis of Parkinson’s disease. Eur J Neurol. 2002;9 Suppl 3:23–30.PubMedCrossRef
7.
Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003;18:467–86.PubMedCrossRef
8.
Barclay CL, Lang AE. Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 1997;62:352–6.PubMedCrossRef
9.
Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord. 1997;12:133–47.PubMedCrossRef
10.
Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009;132(Pt 1):156–71.PubMed
11.
Juh R, Kim J, Moon D, Choe B, Suh T. Different metabolic patterns analysis of Parkinsonism on the 18 F-FDG PET. Eur J Radiol. 2004;51:223–33.PubMedCrossRef
12.
Van Laere K, Casteels C, De Ceuninck L, Vanbilloen B, Maes A, Mortelmans L, et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. J Nucl Med. 2006;47:384–92.PubMed
13.
Schocke MF, Seppi K, Esterhammer R, Kremser C, Jaschke W, Poewe W, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology. 2002;58:575–80.PubMedCrossRef
14.
15.
Pirker W, Asenbaum S, Bencsits G, Prayer D, Gerschlager W, Deecke L, et al. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord. 2000;15:1158–67.PubMedCrossRef
16.
Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson’s disease and multiple system atrophy. Mov Disord. 2001;16:1023–32.PubMedCrossRef
17.
Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med. 1998;39:1521–30.PubMed
18.
Kim JS. Practical Approach for the Clinal Use of Dopamine Transporter Imaging. Nucl Med Mol Imaging. 2008;42(6):425–34.
19.
Maqsood Y, Ronald B, van Berckel BNM, Ponsen MM, Mark L, Windhorst AD, et al. Quantification of dopamine transporter binding using [18 F]FP-β-CIT and positron emmision tomography. J Cereb Blood Flow & Metabol. 2007;27:1397–406.CrossRef
20.
Kim JS. Quantitative analysis and reproducibility of dopamine transporter density using [18 F]FPCIT positron emission tomography. Ph.D. Thesis, Seoul National University, February 2006.
21.
Sokoloff L. Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. Fed Proc. 1981;40:2311–6.PubMed
22.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of Idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Nerosurg Psychiatry. 1992;55(3):181–4.CrossRef
23.
Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670–6.PubMedCrossRef
24.
Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998;55:969–78.PubMedCrossRef
25.
Lee SJ, Oh SJ, Chi DY, Kang SH, Kil HS, Kim JS, et al. One-step high-radiochemical-yield synthesis of [18 F]FP-CIT using a protic solvent system. Nucl Med Biol. 2007;34:345–51.PubMedCrossRef
26.
Kwon KY, Choi CG, Kim JS, Lee MC, Chung SJ. Comparison of brain MRI and 18 F-FDG PET in the differential diagnosis of multiple system atrophy from Parkinson’s disease. Mov Disord. 2007;22:2352–8.PubMedCrossRef
27.
Kasanuki K, Iseki E, Fujishiro H, Yamamoto R, Higashi S, Minegishi M, et al. Neuropathological investigation of the hypometabolic regions on positron emission tomography with [(18)F] fluorodeoxyglucose in patients with dementia with Lewy bodies. J Neurol Sci. 2012;314:111–9.PubMedCrossRef
28.
Kimura N, Hanaki S, Masuda T, Hanaoka T, Hazama Y, Okazaki T, et al. Brain perfusion differences in Parkinsonian disorders. Mov Disord. 2011;26(14):2530–7.PubMedCrossRef
29.
Sun FT, Schriber RA, Greenia JM, He J, Gitcho A, Jagust WJ. Automated template-based PET region of interest analyses in the aging brain. NeuroImage. 2007;34:608–17.PubMedCrossRef
30.
Oh SW, Kim YK, Lee BC, Kim BS, Kim JS, Kim JM, et al. Evaluation of Multiple System Atrophy and Early Parkinson’s Disease Using 123I-FP-CIT SPECT. Nucl Med Mol Imaging. 2009;43:10–8.
31.
Kim BS, Jang SJ, Eo JS, Park EK, Kim YK, Kim JM, et al. The Discriminating Nature of Dopamine Transporter Image in Parkinsonism: The Competency of Dopaminergic Transporter Imaging in Differential Diagnosis Of Parkinsonism: 123I-FP-CIT SPECT Study. Nucl Med Mol Imaging. 2007;41:272–9.
32.
Morrish PK, Sawle GV, Brooks DJ. Clinical and [18 F] dopa PET findings in early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1995;59:597–600.PubMedCrossRef
33.
Marek K, Innis R, van Dyck C, Fussell B, Early M, Eberly S, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression. Neurology. 2001;57:2089–94.PubMedCrossRef
34.
Antonini A, Benti R, De Notaris R, Tesei S, Zecchinelli A, Sacilotto G, et al. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci. 2003;24:149–50.PubMedCrossRef
35.
Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab. 1994;14:783–801.PubMedCrossRef
36.
Brooks DJ. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci. 1993;115:1–17.PubMedCrossRef
37.
Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. FDG PET in the differential diagnosis of parkinsonian disorders. NeuroImage. 2005;26:912–21.PubMedCrossRef
38.
Bosman T, Van Laere K, Santens P. Anatomically standardised 99mTc-ECD brain perfusion SPET allows accurate differentiation between healthy volunteers, multiple system atrophy and idiopathic Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2003;30:16–24.PubMedCrossRef
39.
Wong CY, Thie J, Gaskill M, Ponto R, Hill J, Tian HY, et al. A statistical investigation of normal regional intra-subject heterogeneity of brain metabolism and perfusion by F-18 FDG and O-15 H2O PET imaging. BMC Nucl Med. 2006;6:4.PubMedCrossRef
40.
Meyer PT, Hellwig S, Amtage F, Rottenburger C, Sahm U, Reuland P, et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J Nucl Med. 2011;52:393–400.PubMedCrossRef
41.
Litvan I, Goetz CG, Jankovic J, Wenning GK, Booth V, Bartko JJ, et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol. 1997;54:937–44.PubMedCrossRef
Metadaten
Titel
Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging
verfasst von
Soyoung Jin
Minyoung Oh
Seung Jun Oh
Jungsu S. Oh
Sang Ju Lee
Sun Ju Chung
Chong Sik Lee
Jae Seung Kim
Publikationsdatum
01.03.2013
Verlag
Springer-Verlag
Erschienen in
Nuclear Medicine and Molecular Imaging / Ausgabe 1/2013
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-012-0182-4

Weitere Artikel der Ausgabe 1/2013

Nuclear Medicine and Molecular Imaging 1/2013 Zur Ausgabe

Original Article

Diagnostic Performance of Breast-Specific Gamma Imaging (BSGI) for Breast Cancer: Usefulness of Dual-Phase Imaging with 99mTc-sestamibi

Case Report

Paraneoplastic Cerebellar Degeneration as Initial Presentation of Papillary Carcinoma of the Fallopian Tube: Evaluation and Usefulness of 18F-FDG PET-CT. Case Report and Literature Review

Interesting Image

Bone Scan and SPECT/CT Findings in Marble Bone Disease

Original Article

Photo-Guided Sentinel Node Mapping in Breast Cancer Using Marker-Free Photo-Gamma Fusion Lymphoscintigraphy

Case Report

Ovarian Teratoma Mimicking Metastasis on I-131 Scan : A Case Report

Interesting Image

18F-FDG PET-CT for Detection of Recurrent Spinal Ependymoma